A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials

Investigator-initiated drug trials (IITs) are essential for advancing independent, hypothesis-driven clinical research and addressing unmet therapeutic questions. However, conducting randomized controlled trials frequently requires access to matching placebos to ensure methodological rigor and minimize bias. Obtaining suitable placebos remains a significant logistical, regulatory, and financial challenge, particularly in non-industry-sponsored research. Barriers such as manufacturing constraints, intellectual property restrictions, regulatory approval processes, and limited commercial incentives can delay or compromise trial execution. This meta-research study evaluates the scope, nature, and impact of placebo procurement challenges in investigator-initiated drug trials and explores potential strategies to overcome these barriers.